Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.
Chi-Med is listed on the London Stock Exchange’s AIM market and on the Nasdaq Global Select Market (AIM/Nasdaq: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.
Chi-Med’s Innovation Platform has developed and progressed a broad pipeline of novel oral drug candidates for cancer and inflammation which is in development in North America, Europe, Greater China and Australia. Chi-Med has also developed a profitable Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products.